Abstract
We take the liberty and opportunity to discuss adverse events and event reporting in patients with chronic myeloid leukemia (CML) treated with second generation BCR/ABL1-targeting drugs. The study of Ahmet Emre Eskazan[1][1] suggests that CML patients treated with low-dose dasatinib (100 mg daily)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
